RESUMEN
Microparticles (MPs) are small vesicles released from the membrane surface during eukaryotic cell activation or apoptosis. They originate from various cell types, displaying the typical surface cell proteins and cytoplasmic components of their cell origin. Their procoagulant properties are linked to phosphatidylserine exposed at their surface. Numerous reports have shown that MPs are able to mediate long-range signaling, acting on different targets from those of their own cellular origin. MPs-mediated binding to other cells occurs by integration into the membrane, by adhesion to the cell surface or by ligand-receptor interaction. Elevated levels of circulating MPs have been detected in cardiovascular and immune-mediated diseases. Despite extensive studies of the procoagulant and pro-inflammatory properties of MPs, little is known about their effect on vascular function. MPs accumulate in atherosclerotic plaques and injured vascular wall. Circulating MPs from patients with myocardial infarction induce endothelial dysfunction by impairing the endothelial nitric oxide (NO) pathway, without causing changes in endothelial NO-synthase (eNOS) expression. However, MPs from T-cells may induce endothelial dysfunction, altering gene expression of eNOS and caveolin-1. Moreover, MPs may promote the expression of pro-inflammatory proteins implicated in vascular contractility alterations. This review describes the origin of MPs and their biological role in physiological conditions and in various pathological states, with special reference to the possible linkage between their pro-inflammatory and procoagulant properties and vascular dysfunction.
Asunto(s)
Membrana Celular/fisiología , Proteínas de la Membrana/farmacología , Proteínas de la Membrana/fisiología , Animales , Apoptosis/fisiología , Vasos Sanguíneos/fisiología , Membrana Celular/química , Humanos , Inflamación/fisiopatologíaRESUMEN
Recent evidence suggests that apoptosis in post-mitotic neurons involves an aborted attempt of cells to re-enter the cell cycle which is characterized by increased expression of cyclins, such as cyclin D1, prior to death. However, such cyclins activation prior to apoptotic cell death remains controversial. Many neurological disorders are characterized by neuronal loss, particularly amyotrophic lateral sclerosis (ALS). ALS is a motoneuronal degenerative condition in which motoneuron loss could be due to an inappropriate return of these cells in the cell cycle. In the present study, we observed that deprivation of neurotrophic factor in purified motoneuron cultures induces an apoptotic pathway. After neurotrophic factor withdrawal, DAPI (4,6-diamidin-2-phenylindol dichlorohydrate) staining revealed the presence of nuclear condensation, DNA fragmentation, and perinuclear apoptotic body. Similarly, release of apoptotic microparticles and activation of caspases-3 and -9 were observed within the first hours following neurotrophic factor withdrawal. Next, we tested whether inhibition of cell cycle-related cyclin-dependent kinases (cdks) can prevent motoneuronal cell death. We showed that three cdk inhibitors, olomoucine, roscovitine and flavopiridol, suppress the death of motoneurons. Finally, we observed early increases in cyclin D1 and cyclin E expression after withdrawal of neurotrophic factors. These findings support the hypothesis that after removal of trophic support, post-mitotic neuronal cells die due to an attempt to re-enter the cell cycle in an uncoordinated and inappropriate manner.
Asunto(s)
Apoptosis/efectos de los fármacos , Quinasas Ciclina-Dependientes/antagonistas & inhibidores , Mitosis , Neuronas Motoras/citología , Neuronas Motoras/efectos de los fármacos , Inhibidores de Proteínas Quinasas/farmacología , Animales , Supervivencia Celular/efectos de los fármacos , Células Cultivadas , Ciclina D1/metabolismo , Ciclina E/metabolismo , Quinasas Ciclina-Dependientes/metabolismo , Flavonoides/farmacología , Cinetina/farmacología , Ratones , Factores de Crecimiento Nervioso/deficiencia , Piperidinas/farmacología , Purinas/farmacología , RoscovitinaRESUMEN
BACKGROUND: In multicellular organisms, apoptosis and subsequent microparticle shedding play a key role in homeostasis. Having long been considered as << cellular dust >>, microparticles released in biological fluids upon cell activation or apoptosis appear as multifunctional bioeffectors involved in the modulation of key functions including immunity, inflammation, hemostasis and thrombosis, angiogenesis. MP constitute reliable markers of vascular damage, accessible to biological detection whilst the cells they originate from remain sequestered in tissues or are promptly submitted to phagocytosis. RECENT FINDINGS: MP modulate biological functions of target cells through the transfer of cytoplasmic content, lipids and membrane receptors. The pharmacological modulation of circulating levels of microparticles could be of particular interest in thrombotic or inflammatory diseases, cancer or hemophilia. CONCLUSION: MP can now be viewed not only as a hallmark of cell damage but also as a true biological tool.
Asunto(s)
Apoptosis/fisiología , Biomarcadores , Inflamación/fisiopatología , Tromboplastina/fisiología , Trombosis/fisiopatología , Adulto , Comunicación Celular/fisiología , Membrana Celular/fisiología , Citoesqueleto/fisiología , Femenino , Hemostasis , Homeostasis , Humanos , Inmunidad/fisiología , Masculino , Microcuerpos/fisiología , Tamaño de la Partícula , Fagocitosis , Fenotipo , Embarazo , Selectinas/fisiologíaRESUMEN
Because expressed at a significant level at the membrane of human T cells, we made the hypothesis that the cellular prion protein (PrPc) could behave as a receptor, and be responsible for signal transduction. PrPc engagement by specific antibodies was observed to induce an increase in cytosolic calcium concentration and led to enhanced activity of Src protein tyrosine kinases. Antibodies to CD4 and CD59 did not influence calcium fluxes or signaling. The effect was maximal after the formation of a network involving avidin and biotinylated antibody to PrPc and was inhibited after raft disruption. PrPc localization was not restricted to rafts in resting cells but engagement was a prerequisite for signaling induction, with concomitant PrPc recruitment into rafts. These results suggest a role for PrPc in signaling pathways, and show that lateral redistribution of the protein into rafts is important for subsequent signal transduction.
Asunto(s)
Microdominios de Membrana/metabolismo , Priones/química , Anticuerpos Monoclonales/química , Avidina/farmacología , Western Blotting , Antígenos CD4/biosíntesis , Antígenos CD59/biosíntesis , Calcio/química , Calcio/metabolismo , Línea Celular , Centrifugación por Gradiente de Densidad , Reactivos de Enlaces Cruzados/farmacología , Citosol/metabolismo , Ácido Egtácico/farmacología , Células Endoteliales/metabolismo , Citometría de Flujo , Humanos , Ionóforos , Microscopía Fluorescente , Transducción de Señal , Sacarosa/farmacología , Linfocitos T/metabolismo , Familia-src Quinasas/metabolismoAsunto(s)
Membrana Celular/patología , Hemostasis , Biomarcadores/sangre , Células Sanguíneas/patología , Células Sanguíneas/ultraestructura , Endotelio Vascular/patología , Endotelio Vascular/ultraestructura , Humanos , Inflamación/diagnóstico , Métodos , Tamaño de la Partícula , Estándares de Referencia , Trombosis/diagnósticoRESUMEN
Circulating procoagulant microparticles (MP) were measured as markers of vascular damage and prothrombotic risk in patients undergoing ST-segment myocardial infarction (STEMI) treated by primary percutaneous transluminal coronary angioplasty (PTCA) and additional GPIIb-IIIa antagonists. Cells possibly more responsive to GPIIb-IIIa (alpha(IIb)beta(3)) antagonists were evidenced through MP phenotypes by comparison with healthy volunteers (HV) and STEMI patients treated by PTCA without GPIIb-IIIa antagonist (CP). In 50 STEMI patients, blood samples were collected at day 1 and day 6. Circulating procoagulant MP were captured on annexin V and quantified by prothrombinase assay as nanomolar phosphatidylserine equivalents (nm PhtdSer). Platelet activation by thrombin was confirmed through independent measurement of soluble GPV (sGPV). With respect to HV, procoagulant MP levels were high in patients with STEMI or unstable angina, platelet-derived MP and elevated sGPV testifying to significant platelet activation. A substantial release of endothelial-derived MP was evidenced simultaneously. In abciximab-treated patients, procoagulant MP, mainly of platelet origin, decreased precociously at day 1 (4.2 +/- 0.6 vs. CP 15.5 +/- 2.1 nm PhtdSer; P = 0.001) together with sGPV (36 +/- 3 vs. CP 58 +/- 8 ng mL(-1); P = 0.02). Leukocyte-derived MP decreased at day 6 (0.12 +/- 0.04 vs. CP 0.56 +/- 0.12 nm PhtdSer; P = 0.01) suggesting a possible effect on underlying inflammatory status. In patients presenting cardiovascular events at 6-month follow-up, procoagulant MP levels at day 1 could be indicative of a worsened outcome. MP could constitute a relevant parameter for the follow-up of STEMI patients treated by GPIIb-IIIa antagonists.
Asunto(s)
Angioplastia Coronaria con Balón/efectos adversos , Infarto del Miocardio/sangre , Inhibidores de Agregación Plaquetaria/farmacología , Complejo GPIIb-IIIa de Glicoproteína Plaquetaria/antagonistas & inhibidores , Complejo GPIb-IX de Glicoproteína Plaquetaria/análisis , Trombofilia/tratamiento farmacológico , Abciximab , Antagonistas Adrenérgicos beta/uso terapéutico , Adulto , Anciano , Anticuerpos Monoclonales/farmacología , Anticuerpos Monoclonales/uso terapéutico , Aspirina/uso terapéutico , Biomarcadores/sangre , Femenino , Estudios de Seguimiento , Humanos , Fragmentos Fab de Inmunoglobulinas/farmacología , Fragmentos Fab de Inmunoglobulinas/uso terapéutico , Masculino , Persona de Mediana Edad , Infarto del Miocardio/terapia , Tamaño de la Partícula , Inhibidores de Agregación Plaquetaria/uso terapéutico , Complejo GPIb-IX de Glicoproteína Plaquetaria/efectos de los fármacos , Valor Predictivo de las Pruebas , Pronóstico , Solubilidad , Trombofilia/diagnóstico , Trombofilia/etiologíaRESUMEN
Endothelial apoptosis and platelet activation play a key role in atherothrombotic event. These two mechanisms resulting membrane thickening leading to procoagulant microparticle (MP) liberation into the blood stream. In the vascular compartment, MP contribute to increased thrombin formation, to platelet activation, and prolong inflammation of the arterial wall by inducing the synthesis of cytokines and adhesion of glycoproteins by the endothelial cells. In diabetic patients, increased endothelial apoptosis associated with intense platelet and monocytic activation could contribute to accelerated atherothrombosis. Endothelial, platelet and monocytic derived MP, found in high concentrations in these patients, induce a prothrombotic, proadhesive and proinflammatory tendency in the vascular comportment which could directly impact on the vascular prognosis. In diabetes, increased platelet or monocytic MP is a marker for microvascular disease. Likewise, in acute coronary syndromes of diabetic patients, high concentrations of procoagulant MP could be associated with a poor cardiovascular prognosis. In these diabetic patients, many treatments (antioxidant, antiplatelet, lipid lowering, antihypertensive) significantly reduce the levels of MP and parameters associated with inflammation. MP are one of the key factors linking inflammation, oxidative stress, apoptosis and thrombosis in accelerated atherothrombotic disease of the diabetic. In future, the measurement of MP should help evaluate the efficacy of antioxidant and antiplatelet therapy, especially in diabetic patients.
Asunto(s)
Apoptosis , Arteriosclerosis/fisiopatología , Complicaciones de la Diabetes , Trombosis/fisiopatología , Antioxidantes/uso terapéutico , Endotelio/patología , Humanos , Inflamación , Estrés Oxidativo , Tamaño de la Partícula , Inhibidores de Agregación Plaquetaria/uso terapéuticoRESUMEN
During myocardial infarction (MI), high levels of circulating procoagulant microparticles (MP) shed from endothelial cells and platelets diffuse prothrombotic and proinflammatory potentials crucial for the coronary prognosis. In addition to conventional treatments, we evaluated whether vitamin C treatment could modify circulating levels of procoagulant MP. Upon admission, 61 patients with MI were prospectively randomized for immediate additional vitamin C treatment. Circulating MP were quantified by functional prothrombinase assay before and after 5 days of vitamin C administration (1 g day-1). The cellular origin of MP was also assessed. In vitamin C-treated patients, the reduction in platelet-derived MP was 10% higher (P = 0.01). In patients with diabetes mellitus, dyslipidemia or more than two cardiovascular risk factors, vitamin C decreased endothelial and platelet-derived MP levels by approximately 70% and 13%, respectively. This early effect on circulating platelet and endothelial-derived MP, testifies to the importance of oxidative stress during MI. Vitamin C could prove beneficial for the outcome of patients at higher thrombotic risk.
Asunto(s)
Ácido Ascórbico/uso terapéutico , Endotelio Vascular/efectos de los fármacos , Endotelio Vascular/metabolismo , Infarto del Miocardio/sangre , Infarto del Miocardio/tratamiento farmacológico , Activación Plaquetaria/efectos de los fármacos , Enfermedad Aguda , Anciano , Plaquetas/metabolismo , Cardiotónicos/uso terapéutico , Angiografía Coronaria , Endotelio Vascular/patología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Infarto del Miocardio/patología , Activación Plaquetaria/fisiología , Estudios Prospectivos , Factores de Riesgo , Tromboplastina/metabolismoRESUMEN
BACKGROUND: Proinflammatory cytokines like tumor necrosis factor-alpha and oxidative stress induce apoptotic cell death in endothelial cells (ECs). Systemic inflammation and increased oxidative stress in congestive heart failure (CHF) coincide with enhanced EC apoptosis and the development of endothelial dysfunction. Therefore, we investigated the effects of antioxidative vitamin C therapy on EC apoptosis in CHF patients. METHODS AND RESULTS: Vitamin C dose dependently suppressed the induction of EC apoptosis by tumor necrosis factor-alpha and angiotensin II in vitro as assessed by DNA fragmentation, DAPI nuclear staining, and MTT viability assay. The antiapoptotic effect of vitamin C was associated with reduced cytochrome C release from mitochondria and the inhibition of caspase-9 activity. To assess EC protection by vitamin C in CHF patients, we prospectively randomized CHF patients in a double-blind trial to vitamin C treatment versus placebo. Vitamin C administration to CHF patients markedly reduced plasma levels of circulating apoptotic microparticles to 32+/-8% of baseline levels, whereas placebo had no effect (87+/-14%, P<0.005). In addition, vitamin C administration suppressed the proapoptotic activity on EC of the serum of CHF patients (P<0.001). CONCLUSIONS: Administration of vitamin C to CHF patients suppresses EC apoptosis in vivo, which might contribute to the established functional benefit of vitamin C supplementation on endothelial function.
Asunto(s)
Apoptosis/efectos de los fármacos , Ácido Ascórbico/administración & dosificación , Endotelio Vascular/efectos de los fármacos , Insuficiencia Cardíaca/tratamiento farmacológico , Administración Oral , Adulto , Anciano , Angiotensina II/farmacología , Biomarcadores/sangre , Supervivencia Celular/efectos de los fármacos , Células Cultivadas , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Endotelio Vascular/citología , Endotelio Vascular/fisiopatología , Inhibidores Enzimáticos/farmacología , Femenino , Insuficiencia Cardíaca/fisiopatología , Humanos , Inyecciones Intravenosas , Masculino , Persona de Mediana Edad , Estrés Oxidativo/efectos de los fármacos , Estudios Prospectivos , Sustancias Reactivas al Ácido Tiobarbitúrico/metabolismo , Factor de Necrosis Tumoral alfa/metabolismo , Factor de Necrosis Tumoral alfa/farmacologíaRESUMEN
The mechanism underlying the prothrombotic state that characterizes the primary antiphospholipid syndrome proves to be difficult to define mainly because of the variety of the phospholipid and protein targets of antiphospholipid antibodies that have been described. Much of the debate is related to the use of polyclonal antibodies during the different antiphospholipid assays. To better describe the antiphospholipid antibodies, a strategy was designed to analyze the reactivity of each one antibody making up the polyclonal anticardiolipin activity, breaking down this reactivity at the clonal level. This was performed in a single patient with primary antiphospholipid syndrome by combining (1) the antigen-specific selection of single cells sorted by flow cytometry using structurally bilayered labeled anionic phospholipids and (2) the cloning of immunoglobulin (Ig) variable (V) region genes originating from individual IgG anticardiolipin-specific B cells by a single-cell polymerase chain reaction technique. The corresponding V regions were cloned in order to express human recombinant antibodies in insect cells by a baculovirus expression system. The molecular analysis, the fine specificity, and the protein cofactor dependency of the first 5 monoclonal IgG anticardiolipins are reported here. This clonal analysis reveals the extreme heterogeneity of these antibodies, which could account for the difficulties in the previous attempts to define the pathogenic antiphospholipid response. This approach should help to unravel the complex antiphospholipid immune response and the mechanism of the prothrombotic state associated with these antibodies, but it could also shed some light on their possible origins. (Blood. 2001;97:3820-3828)
Asunto(s)
Anticuerpos Anticardiolipina/sangre , Síndrome Antifosfolípido/inmunología , Clonación Molecular/métodos , Adulto , Anticuerpos Anticardiolipina/genética , Anticuerpos Anticardiolipina/metabolismo , Anticuerpos Monoclonales/análisis , Anticuerpos Monoclonales/inmunología , Diversidad de Anticuerpos , Especificidad de Anticuerpos , Linfocitos B/inmunología , Cardiolipinas/metabolismo , Femenino , Genes de Inmunoglobulinas , Humanos , Inmunoglobulina G/inmunología , Inhibidor de Coagulación del Lupus/metabolismoRESUMEN
One of the frequently proposed mechanisms for pregnancy losses refers to uteroplacental thrombosis. However the contribution of classical thrombotic risk factors remains questionable and, if real, does not account for a large number of pregnancy losses. The aim of this study was to investigate the presence of circulating procoagulant microparticles, a new marker of cell activation already associated with various prothrombotic clinical settings. Microparticles were assessed by an original prothrombinase assay on platelet depleted plasma obtained from 74 women with a history of pregnancy loss without apparent cause and 50 controls. Patients were studied at least 2 months after the last obstetrical event and were classified into 2 groups: 49 women with at least 3 consecutive spontaneous abortions at or before the 10th postmenstrual week and 25 with at least one fetal death beyond the 10th postmenstrual week. Among the 74 patients, 41 had increased levels of circulating microparticles, 29 belonging to the group of early pregnancy loss (59%) and 12 to the group of late pregnancy loss (48%). The high prevalence of increased levels of procoagulant microparticles in both groups makes this new marker very promising for the understanding, follow up and therapeutical handling of pregnancy loss.
Asunto(s)
Aborto Espontáneo/sangre , Factores de Coagulación Sanguínea/efectos adversos , Gránulos Citoplasmáticos/química , Aborto Habitual/sangre , Aborto Habitual/etiología , Aborto Espontáneo/etiología , Adulto , Circulación Sanguínea , Factores de Coagulación Sanguínea/ultraestructura , Membrana Celular/metabolismo , Membrana Celular/ultraestructura , Estudios de Cohortes , Femenino , Edad Gestacional , Humanos , Embarazo , Complicaciones Hematológicas del Embarazo/sangre , Complicaciones Hematológicas del Embarazo/etiología , Estudios RetrospectivosRESUMEN
OBJECTIVES: The purposes of this study were to determine whether the serum of patients with congestive heart failure (CHF) can induce apoptosis of endothelial cells and to elucidate the underlying mechanisms. Moreover, the effect of the beta-blocker carvedilol was investigated. BACKGROUND: Congestive heart failure is associated with impaired endothelial function in the peripheral systemic vasculature and with systemic release of inflammatory cytokines. Pro-inflammatory cytokines have been shown to induce endothelial cell apoptosis in vitro. Therefore, we hypothesized that CHF is associated with enhanced apoptosis of endothelial cells. METHODS: Human umbilical vein endothelial cells were exposed to the serum of patients with CHF (n = 15) or healthy volunteers (n = 11), and apoptosis was determined by fluorescence staining of the nuclei and demonstration of deoxyribonucleic acid laddering. Moreover, apoptotic membrane particles were detected in plasma samples of patients with CHF. RESULTS: The serum of patients with CHF revealed a significantly enhanced pro-apoptotic activity as compared with age- and gender-matched healthy volunteers (p < 0.001). Furthermore, patients with CHF revealed significantly elevated plasma concentrations of apoptotic membrane particles. Apoptosis of endothelial cells correlated with elevated tumor necrosis factor-alpha (TNF-alpha) (r = 0.585, p = 0.002) and soluble TNF receptor serum levels (r = 0.517, p = 0.007). Carvedilol completely suppressed the increase in apoptosis induced by the serum of patients with CHF. Moreover, carvedilol dose-dependently inhibited TNF-alpha-induced apoptosis. The antiapoptotic activity of carvedilol was mediated by reduced activation of the caspase cascade through inhibition of mitochondrial cytochrome c release. The suppression of apoptosis by carvedilol was due to its antioxidative rather than beta-blocking effects, as the analogue BM91.0228, which has no beta-blocking activity, exerted similar effects. CONCLUSIONS: These findings indicate that endothelial cell apoptosis may play a role in the pathophysiology of heart failure. Inhibition of endothelial cell apoptosis by carvedilol may contribute to the beneficial effects of carvedilol in patients with heart failure.
Asunto(s)
Antagonistas Adrenérgicos beta/uso terapéutico , Antioxidantes/farmacología , Apoptosis/efectos de los fármacos , Carbazoles/farmacología , Insuficiencia Cardíaca/fisiopatología , Propanolaminas/farmacología , Anciano , Antioxidantes/uso terapéutico , Carvedilol , Células Cultivadas , Grupo Citocromo c/metabolismo , Células Epiteliales/fisiología , Femenino , Insuficiencia Cardíaca/sangre , Humanos , Masculino , Persona de Mediana EdadRESUMEN
BACKGROUND: Apoptotic microparticles are responsible for almost all tissue factor activity of the plaque lipid core. We hypothesized that elevated levels of procoagulant microparticles could also circulate in the peripheral blood of patients with recent clinical signs of plaque disruption and thrombosis. METHODS AND RESULTS: We studied 39 patients with coronary heart disease, including 12 patients with stable angina and 27 patients with acute coronary syndromes (ACS), and 12 patients with noncoronary heart disease. We isolated the circulating microparticles by capture with annexin V and determined their procoagulant potential with a prothrombinase assay. The cell origins of microparticles were determined in an additional 22 patients by antigenic capture with specific antibodies. The level of procoagulant microparticles did not differ between stable angina patients and noncoronary patients (10.1+/-1.6 nmol/L phosphatidylserine [PS] equivalent versus 9.9+/-1.6 nmol/L PS equivalent, respectively). However, procoagulant microparticles were significantly elevated in patients with ACS (22.2+/-2.7 nmol/L PS equivalent) compared with other coronary (P<0.01) or noncoronary (P<0.01) patients. Microparticles of endothelial origin were significantly elevated in patients with ACS (P<0.01), which suggests an important role for endothelial injury in inducing the procoagulant potential. CONCLUSIONS: High levels of procoagulant endothelial microparticles are present in the circulating blood of patients with ACS and may contribute to the generation and perpetuation of intracoronary thrombi.
Asunto(s)
Angina de Pecho/sangre , Antígenos CD , Enfermedad de la Arteria Coronaria/complicaciones , Trombosis Coronaria/sangre , Glicoproteínas de Membrana , Moléculas de Adhesión de Célula Nerviosa , Trombofilia/etiología , Tromboplastina/análisis , Enfermedad Aguda , Apoptosis , Antígeno CD146 , Enfermedad de la Arteria Coronaria/sangre , Trombosis Coronaria/etiología , Endotelio Vascular/lesiones , Endotelio Vascular/metabolismo , Endotelio Vascular/patología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Fosfatidilserinas/sangre , Molécula-1 de Adhesión Celular Endotelial de Plaqueta/análisis , Estudios Prospectivos , Receptores de Superficie Celular/análisis , Trombofilia/sangreRESUMEN
Paroxysmal nocturnal hemoglobinuria (PNH), frequently occurring during suppressed hematopoiesis including aplastic anemia (AA), is a clonal disorder associated with an increased incidence of thrombotic events. Complement-mediated hemolysis, impairment of the fibrinolytic system, or platelet activation are thought to be responsible for the associated thrombotic risk. We investigated here the elevation of membrane-derived procoagulant microparticles in the blood flow of such patients. Elevated levels of circulating microparticles were in fact detected in both de novo PNH patients and AA subjects with a PNH clone, but not in those with AA without a PNH clone. The cellular origin of the microparticles was determined in PNH samples; most stemmed from platelets. Glycophorin A+ particles were rarely detected. Therefore, platelet activation, resulting in the dissemination of procoagulant phospholipids in the blood flow, could be one of the main causes for the elevated thrombotic risk associated with PNH. These observations suggest that shed membrane particles can be considered a valuable biological parameter for the assessment of possible thrombotic complications in patients with PNH.
Asunto(s)
Anemia Aplásica/sangre , Factores de Coagulación Sanguínea/análisis , Hemoglobinuria Paroxística/sangre , Anemia Aplásica/complicaciones , Anticuerpos Monoclonales , Eritrocitos/fisiología , Citometría de Flujo , Glicoforinas/análisis , Hemoglobinuria Paroxística/complicaciones , Humanos , Fosfatidilserinas/sangre , Activación Plaquetaria , Complejo GPIb-IX de Glicoproteína Plaquetaria/análisis , Factores de Riesgo , Trombosis/etiologíaRESUMEN
Phosphatidylserine exposure in the exoplasmic leaflet of the plasma membrane is one of the early hallmarks of cells undergoing apoptosis. The shedding of membrane particles carrying Ags testifying to their tissue origin is another characteristic feature. Annexin V, a protein of as yet unknown specific physiologic function, presents a high Ca2+-dependent affinity for phosphatidylserine and forms two-dimensional arrays at the membrane surface. In this study, we report the delaying action of annexin V on apoptosis in the CEM human T cell line expressing CD4 and the normal cellular prion protein (PrPc), two Ags of particular relevance to cell degeneration and with different attachments to the membrane. The effect of annexin V was additive to that of z-Val-Ala-Asp-fluoromethyl ketone, a potent caspase inhibitor. Annexin V significantly reduced the degree of proteolytic activation of caspase-3, and totally blocked the release of CD4+ and PrPc+ membrane particles. z-Val-Ala-Asp-fluoromethyl ketone was a more powerful antagonist of caspase-3 processing, but prevented the shedding of CD4+ vesicles only partially and had no effect on that of PrPc+ ones. These results suggest that an external membrane constraint, such as that exerted by annexin V, has important consequences on the course of programmed cell death and on the dissemination of particular Ags. In vivo, annexin V had a significant protective effect against spleen weight loss in mice treated by an alkylating agent previously shown to induce lymphocyte apoptosis.
Asunto(s)
Anexina A5/farmacología , Apoptosis/efectos de los fármacos , Antígenos CD4/efectos de los fármacos , Proteínas PrPC/efectos de los fármacos , Linfocitos T/efectos de los fármacos , Animales , Antígenos de Superficie/efectos de los fármacos , Caspasa 3 , Inhibidores de Caspasas , Caspasas/metabolismo , Membrana Celular/efectos de los fármacos , Células HL-60 , Humanos , Masculino , Proteínas de la Membrana/efectos de los fármacos , Ratones , Ratones Endogámicos BALB CRESUMEN
BACKGROUND: The specific role of apoptosis in human atherosclerosis remains unknown. During apoptotic cell death, phosphatidylserine exposure on the cell surface confers a high tissue-factor (TF)-dependent procoagulant activity. METHODS AND RESULTS: In this study, we examined the role of apoptotic cell death in the promotion of plaque thrombogenicity. TF expression and its relation to apoptosis was analyzed in 16 human atherosclerotic plaques by the use of immunohistochemical techniques. The presence of shed membrane apoptotic microparticles was analyzed in extracts from 6 human atherosclerotic plaques and 3 underlying arterial walls. The microparticles were captured by annexin V and their amounts estimated with respect to their phospholipid content by use of a prothrombinase assay. The prothrombogenic potential of the microparticles was further assessed by the measurement of total and microparticle-dependent TF activity in the extracts. The cell origin of the microparticles was determined after capture by specific antibodies. We were able to detect marked TF expression in the plaques in close proximity to apoptotic cells and debris, suggesting a potential interaction between TF and the apoptotic cell surfaces. High levels of shed membrane apoptotic microparticles were detected in extracts from atherosclerotic plaques but not in the underlying arterial walls (29.5+/-3.7 nmol/L phosphatidylserine equivalent versus 1.3+/-0.4 nmol/L, respectively, P<0.02). The microparticles were mainly of monocytic and lymphocytic origin and retained 97+/-2% of total TF activity, indicating a direct causal relationship between shed membrane microparticles and procoagulant activity of plaque extracts. CONCLUSIONS: These results indicate that shed membrane microparticles with procoagulant potential are produced in human atherosclerotic plaques. Apoptosis could be a critical determinant of plaque thrombogenicity after plaque rupture.
Asunto(s)
Apoptosis/fisiología , Arteriosclerosis/metabolismo , Endotelio Vascular/metabolismo , Trombosis/metabolismo , Enfermedad Aguda , Arteriosclerosis/patología , Arterias Carótidas/metabolismo , Arterias Carótidas/patología , Membrana Celular/metabolismo , Endotelio Vascular/patología , Humanos , Etiquetado Corte-Fin in Situ , Microesferas , Fosfatidilserinas/metabolismo , Tromboplastina/metabolismoRESUMEN
The short-term consequences on spleen cells of the intraperitoneal administration of nitrogen mustard (HN-2) to mice or of a whole-body gamma irradiation have been evaluated. Experiments were designed to assess the induction of apoptosis in spleen cells following exposure to these agents. The occurrence of this type of cell death was analysed by several methods, in particular the quantification in the blood of phosphotidylserine-bearing microparticles shed by apoptotic cells. In response to HN-2 or radiations, spleens undergo a rapid involution of their weight and cellularity. Ex vivo apoptosis occurs within 24 hours in cultured lymphocytes in a dose-dependent manner after both treatments. As compared with untreated controls, circulating microparticles increased 3-fold after the injection of 5 mg/kg of HN-2.
Asunto(s)
Antineoplásicos Alquilantes/farmacología , Apoptosis , Linfocitos/efectos de los fármacos , Linfocitos/efectos de la radiación , Mecloretamina/farmacología , Bazo/efectos de los fármacos , Bazo/efectos de la radiación , Animales , Fragmentación del ADN , Relación Dosis-Respuesta a Droga , Femenino , Rayos gamma , Interfase , Activación de Macrófagos , Masculino , Ratones , Ratones Endogámicos C3H , Tamaño de los Órganos/efectos de los fármacos , Tamaño de los Órganos/efectos de la radiación , Fagocitosis , Fosfatidilserinas/metabolismo , Bazo/citología , Irradiación Corporal TotalRESUMEN
The plasma membrane remodeling, including the early transverse redistribution of phosphatidylserine, is a general feature occurring in cells in which a death program has been induced. In most cases, studies of this kind have focused mainly on cells. In this study, we report a clear correlation between the degree of apoptosis induced by a variety of agents in several types of cultured cells and the amount of shed membrane microparticles captured in the corresponding supernatants by insolubilized annexin V, a protein showing a strong affinity for phosphatidylserine. Such particles carry membrane antigens specific of the cells they stem from, and through which capture is also feasible. Homologous circulating microparticles were captured in peripheral blood from individuals with HIV-1 infection. A substantial proportion bore CD4 antigen. In some cases, CD4+ particles could be detected even in the absence of circulating CD4+ T cells, testifying to the presence of such resident cells in lymphoid tissues. These results suggest that shed membrane particles are one of the hallmarks of programmed cell death, of particular interest when the corresponding cells are hardly accessible.